Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common gout drug ease a tough type of heart failure?

NCT ID NCT05637398

Symptom relief Sponsor: I.M. Sechenov First Moscow State Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether colchicine, an anti-inflammatory drug, can lower inflammation in people with a specific type of heart failure called HFpEF. 42 adults with heart failure symptoms and signs of inflammation took part. The goal was to see if colchicine could reduce markers of inflammation and improve heart function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

42 people

The number who actually took part.

Started

Dec 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 40 years of age, male and female * Left ventricular ejection fraction (LVEF) ≥ 50% * Symptoms and signs of heart failure * N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥300 pg/ml at baseline (patients in atrial fibrillation at baseline NT-proBNP ≥ 600 pg/ml), left atrial volume index (LAVI) \>34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females * body mass index (BMI) \> 30kg/m2 or diabetes mellitus Exclusion Criteria: * Hypertrophic cardiomyopathy, constrictive pericarditis, or cardiac amyloidosis * Acute decompensation of HF in the last 1 month * Valvular heart disease * Prior history of LVEF below 50% * Acute myocardial infarction in the last 3 months, cardiac surgery or cerebrovascular accident within the recent 6 months * Any active or chronic inflammatory diseases or infections * Patients with indication for colchicine therapy or history of colchicine intolerance * Severe hepatic (alanine aminotransferase N3 upper limit of normal or renal dysfunction (estimated glomerular filtration rate \<45 mL/min per 1.73m2) * Severe nervous system diseases * History of any malignancy or suffering from cancer * Lack of informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colchicine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colchicine poisoning diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colchicine Hfpef - heart failure with preserved ejection fraction

Contacts and locations

Locations

  • A Shchendrygina

    Moscow, 119415, Russia

  • Anastasia Shchendrygina

    Moscow, 119415, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.